<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470353</url>
  </required_header>
  <id_info>
    <org_study_id>I 78706</org_study_id>
    <secondary_id>RPCI-I-78706</secondary_id>
    <nct_id>NCT00470353</nct_id>
  </id_info>
  <brief_title>Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery</brief_title>
  <official_title>A Pilot Study of Low and High Dose Vitamin Cholecalciferol (D3) With Pharmacokinetic and Pharmacodynamic Correlates in Patients With Resected Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: The use of cholecalciferol and calcium carbonate may keep colon cancer from coming&#xD;
      back in patients with colon cancer that has been removed by surgery.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying two different doses of cholecalciferol to&#xD;
      compare how well they work when given together with calcium carbonate in treating patients&#xD;
      with colon cancer that has been removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the antiproliferative effects of 2 different doses of cholecalciferol (i.e.,&#xD;
           vitamin D3) in combination with calcium carbonate on the proliferative labeling index in&#xD;
           patients with resected colon cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the effects of these doses on serum levels of 25-OH-D3, 1,25-OH-D3, 24,25-OH-D3,&#xD;
           calcium, and parathyroid hormone in these patients.&#xD;
&#xD;
        -  Determine the safety of high-dose cholecalciferol in these patients over 2 years.&#xD;
&#xD;
        -  Compare the effects of these doses on several biological markers (i.e., cyclin D1,&#xD;
           protein kinase C, vitamin D receptor, p21, and p27) in the rectal mucosa of these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral low-dose cholecalciferol once daily and oral calcium&#xD;
           carbonate twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral high-dose cholecalciferol once daily and calcium carbonate&#xD;
           as in arm I.&#xD;
&#xD;
      Treatment in both arms continues for up to 2 years in the absence of disease progression or&#xD;
      unacceptable toxicity. All patients undergo sigmoidoscopy or colonoscopy with 4 quadrant&#xD;
      mucosal biopsies at baseline and after 6 months of study treatment. After their 6-month&#xD;
      mucosal biopsy, patients in arm I switch to high-dose cholecalciferol as in arm II.&#xD;
&#xD;
      Patients undergo blood, urine, and tissue collection periodically during study for&#xD;
      pharmacokinetic, pharmacodynamic, and/or histopathological analysis. Serum is collected&#xD;
      monthly for 3 months and then once every 3 months to assess changes in serum levels of&#xD;
      vitamin D and vitamin D metabolites (i.e., 1,25-OH-D3; 25-OH-D3; 24,25-OH-D3), as well as&#xD;
      changes in calcium and parathyroid hormone, BUN, creatinine, electrolytes, and phosphorus&#xD;
      levels. Urine is collected once every 3 months to assess changes in urine calcium and&#xD;
      creatinine levels for hypercalciuria. Tissue biopsies of normal endorectal mucosa collected&#xD;
      at baseline and after 6 months of study treatment are evaluated by IHC for proliferative&#xD;
      index, vitamin D receptor staining, p21, p27, cyclin D1, and protein kinase C.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to poor accrual/lack of funding&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum levels of 25-OH-D3, 1,25-OH-D3, 24,25-OH-D3, calcium, and parathyroid hormone</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of high-dose cholecalciferol supplementation as measured over 2 years</measure>
    <time_frame>over 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  History of colon cancer&#xD;
&#xD;
               -  Underwent resection and has been in clinical remission for ≥ 1 year&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No familial adenomatous polyposis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 1 year&#xD;
&#xD;
          -  No genitourinary stones within the past 5 years&#xD;
&#xD;
          -  No severe comorbid conditions, such as uncompensated heart failure or active&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  No history of hypercalcemia&#xD;
&#xD;
          -  No active colostomy&#xD;
&#xD;
          -  No contraindications to sigmoidoscopy or mucosal biopsies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior rectal surgery or abdominoperineal resection&#xD;
&#xD;
          -  At least 1 month since prior vitamin D or calcium supplementation&#xD;
&#xD;
               -  Prior vitamin D supplemental intake ≤ 800 IU per day&#xD;
&#xD;
          -  At least 1 year since prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
          -  No concurrent active anticoagulation&#xD;
&#xD;
               -  Patients who stop anticoagulation therapy at the time of mucosal biopsy are&#xD;
                  eligible&#xD;
&#xD;
          -  No other concurrent supplemental calcium or vitamin D&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

